trending Market Intelligence /marketintelligence/en/news-insights/trending/r2q_1npknxamvkcodmhyqw2 content esgSubNav
In This List

Brainstorm Cell Therapeutics appoints chief commercial officer

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Brainstorm Cell Therapeutics appoints chief commercial officer

New York-based biotechnology company Brainstorm Cell Therapeutics Inc. appointed Arturo Araya as chief commercial officer, effective Sept. 4.

Araya has served on Brainstorm's board since February 2017. He served as the global head of commercial for Novartis AG unit Novartis Pharmaceuticals Corp.'s cell and gene therapies unit until 2016.

Brainstorm develops stem cell treatments to treat diseases caused by degeneration of the nervous system.